Albhaisi Somaya, Sun Jing, Sanyal Arun J
Department of Internal Medicine, Virginia Commonwealth University, Richmond, VA, United States.
Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, United States.
Front Oncol. 2023 Aug 22;13:1198871. doi: 10.3389/fonc.2023.1198871. eCollection 2023.
Identification of high-risk patients for hepatocellular carcinoma (HCC) is essential for long term monitoring of nonalcoholic steatohepatitis (NASH) cirrhosis progression. We sought to evaluate the association between Fibrosis-4 (FIB-4) index and incidence of HCC risk among patients with NASH cirrhosis.
We conducted a retrospective cohort study of adult patients with NASH cirrhosis (n= 1,338) who were evaluated in a single medical center between 2005 and 2015. Those who developed HCC were identified through electronic medical records using International Classification of Diseases (ICD) 9 and 10 codes until the end of September 2021.
During a median follow-up time of 3.7 years, 157 (11.7%) patients with NASH cirrhosis developed HCC. At index visit, the study population had a median age 57 years, 43% males, 78.8% White, and mean FIB-4 index 4.2. The final multivariable Cox regression model revealed that male sex, BMI 25-29.9 kg/m, and hypertension were independent factors associated with development of HCC in patients with NASH cirrhosis. Compared to patients with FIB-4 ¾ 1.45, patients with FIB-4 between 1.45-3.25 had a similar hazard of HCC (Hazard Ratio [HR] 1.12, 95% CI: 0.67-1.86, p=0.670), whereas patients with FIB-4 >3.25 had a 1.93 (95% CI: 1.22-3.05, p=0.005) increased hazard of HCC.
FIB-4 > 3.25 was an independent factor associated with increased HCC risk among NASH cirrhosis patients. FIB-4 index is a promising tool for determining high-risk patients and may be used in routine clinical practice to monitor risk of HCC in patients with NASH cirrhosis.
识别肝细胞癌(HCC)的高危患者对于长期监测非酒精性脂肪性肝炎(NASH)肝硬化的进展至关重要。我们旨在评估纤维化-4(FIB-4)指数与NASH肝硬化患者发生HCC风险之间的关联。
我们对2005年至2015年间在单一医疗中心接受评估的成年NASH肝硬化患者(n = 1338)进行了一项回顾性队列研究。通过电子病历使用国际疾病分类(ICD)9和10编码确定那些发生HCC的患者,直至2021年9月底。
在中位随访时间3.7年期间,157例(11.7%)NASH肝硬化患者发生了HCC。在初次就诊时,研究人群的中位年龄为57岁,男性占43%,白人占78.8%,平均FIB-4指数为4.2。最终的多变量Cox回归模型显示,男性、体重指数(BMI)25 - 29.9 kg/m²和高血压是与NASH肝硬化患者发生HCC相关的独立因素。与FIB-4≤1.45的患者相比,FIB-4在1.45 - 3.25之间的患者发生HCC的风险相似(风险比[HR] 1.12,95%置信区间:0.67 - 1.86,p = 0.670),而FIB-4 > 3.25的患者发生HCC的风险增加了1.93倍(95%置信区间:1.22 - 3.05,p = 0.005)。
FIB-4 > 3.25是与NASH肝硬化患者HCC风险增加相关的独立因素。FIB-4指数是确定高危患者的一个有前景的工具,可用于常规临床实践中监测NASH肝硬化患者的HCC风险。